Cargando…
The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
Mutation in KRAS protooncogene represents one of the most common genetic alterations in NSCLC and has posed a great therapeutic challenge over the past ~ 40 years since its discovery. However, the pioneer work from Shokat’s lab in 2013 has led to a recent wave of direct KRAS(G12C) inhibitors that ut...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625227/ https://www.ncbi.nlm.nih.gov/pubmed/37925476 http://dx.doi.org/10.1186/s40164-023-00453-8 |